Virax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private Placement

An update from Virax Biolabs Group Ltd. Class A ( (VRAX) ) is now available.

Virax Biolabs Group Limited, a U.K.-based life sciences and diagnostics company listed in the U.S. as a foreign private issuer, develops and distributes medical and laboratory products while maintaining compliance with U.S. securities disclosure rules. The company’s capital structure includes ordinary shares that are actively issued in connection with private placement transactions.

On December 3, 2025, Virax entered into a private placement with an accredited investor, raising $5 million in gross proceeds through the issuance of pre-funded warrants and preferred investment options. As of April 10, 2026, the company reported that all 12,500,000 pre-funded warrants had been exercised at a nominal price, increasing its total ordinary shares outstanding to 19,923,432 and signaling full conversion of that portion of the financing into equity.

The most recent analyst rating on (VRAX) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.

More about Virax Biolabs Group Ltd. Class A

Virax Biolabs Group Limited is a life sciences company based in the United Kingdom, listed in the U.S. as a foreign private issuer. The company operates in the biotechnology and diagnostics space, focusing on developing and commercializing medical and laboratory products, with its ordinary shares traded on a public market and subject to U.S. securities reporting requirements.

Average Trading Volume: 6,709,598

Technical Sentiment Signal: Sell

Current Market Cap: $1M

See more insights into VRAX stock on TipRanks’ Stock Analysis page.